tirzepatide injection clover hill Tirzepatide Injection The GLP-1/GIP dual-receptor agonist tirzepatide

The primary outcome was progression to cirrhosis, with secondary outcomes of a composite of associated complications, including decompensation, hepatocellular carcinoma or liver transplant

This table makes one thing abundantly clear: while they share two common targets, retatrutides third mechanism makes it a completely different beast

For Ozempic, this typically involves starting at 0.25 mg weekly for four weeks, then increasing to 0.5 mg weekly

This glucose-dependent mechanism reduces the risk of hypoglycaemia compared to insulin secretagogues such as sulphonylureas, although the risk increases when tirzepatide is used in combination with insulin or sulphonylureas